Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?

Expert Opinion on Investigational Drugs

Volumn 13, Issue 4, 2004, Pages 431-434

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Animal models; Autosomal recessive polycystic kidney disease; Nephronophthisis; OPC 31260; Polycystic kidney disease; V2 receptor antagonist

Indexed keywords

LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; OPC 4106; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ARTICLE; ASCITES; AUTOSOMAL RECESSIVE DISORDER; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; MOUSE; NEPHRONOPHTHISIS; NONHUMAN; RAT; REMISSION; SIDE EFFECT; THIRST;

ANIMALS; BENZAZEPINES; DRUG EVALUATION, PRECLINICAL; HUMANS; POLYCYSTIC KIDNEY DISEASES; RECEPTORS, VASOPRESSIN;

EID: 1842832732     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.4.431     Document Type: Article

References (16)

1. 2 receptor antagonist. Nat. Med. (2003) 9:1323-1326.
2. WILSON PD: Polycystic kidney disease. N. Engl. J. Med. (2004) 350:151-164.
3. 2-receptor-dependent regulation of AQP2 expression in Brattleboro rats. Am. J. Physiol. Renal Physiol. (2000) 279:F370-F382.
4. YAMAGUCHI T, PELLING JC, RAMASWAMY NT et al.: cAMP stimulates the in vitro proliferation of renal cyst epithdial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. (2000) 57:1460-1471.
5. HANAOKA K, GUGGINO W: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. (2000) 11:1179-1187.
6. 2 receptor antagonist. Br. J. Pharmacol. (1992) 105:787-791.
7. 2 antagonist in men. J. Pharmacol. Exp. Ther. (1995) 272:546-551.
8. WARD CJ, HOGAN MC, ROSSETTI S et al.: The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. (2002) 30:259-269.
9. OLBRICH H, FLIEGAUF M, HOEFELE J et al.: Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat. Genet. (2003) 34:455-439.
10. BOSCH-MARCÉ M, POO J-L, JIMÉNEZ W et al.: Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J. Pharmacol. Exp. Ther. (1999) 289:194-201.
11. 2 receptor antagonist, SR121463, in cirrhotic rats. J. Pharmacol. Exp. Ther. (2000) 295:83-90.
12. 2 antagonist in cirrhotic patients with ascites. Hepatology (2002) 36:1197-1205.
13. WONG F, BLEI AT, BLENDIS LM, THYLUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 37:182-191.
14. GERBES AL, GULBERG V, GINES P et al.: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology (2003) 124:933-939.
15. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. (1998) 287:860-867.
16. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690-2696.